AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Pfizer Inc.
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S5V466
30.03▼ 0.39 (-1.28%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
30.42
Day's Range
29.81 – 30.32
52-Week Range
23.62 – 30.44
Volume
29.4M
Avg Volume
30.7M
Share Statistics
Shares Outstanding
Employees
75.0K
Exchange
XNYS
Listed
1951-06-22
Share count as of July 29, 2026

Pfizer Inc. (PFE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Pfizer Inc. (PFE)
What is Pfizer Inc.'s Market Cap?
Pfizer Inc.'s Market Cap is $171.2B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Enterprise Value?
Pfizer Inc.'s Enterprise Value is $233.4B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Trailing P/E?
Pfizer Inc.'s Trailing P/E is 39.5×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Price / Sales?
Pfizer Inc.'s Price / Sales is 2.7×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s EV / Revenue?
Pfizer Inc.'s EV / Revenue is 3.7×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s EV / EBITDA?
Pfizer Inc.'s EV / EBITDA is 17.3×, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Revenue (TTM)?
Pfizer Inc.'s Revenue (TTM) is $63.7B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Net Income (TTM)?
Pfizer Inc.'s Net Income (TTM) is $4.3B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s EBITDA?
Pfizer Inc.'s EBITDA is $13.5B, based on as-reported figures from SEC (XBRL) filings.
What is Pfizer Inc.'s Diluted EPS (TTM)?
Pfizer Inc.'s Diluted EPS (TTM) is 0.76, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PFEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 28, 2026Mar 29, 2026Dec 31, 2025Sep 28, 2025Jun 29, 2025Mar 30, 2025Dec 31, 2024Sep 29, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Oct 1, 2023Jul 2, 2023Apr 2, 2023Dec 31, 2022Oct 2, 2022Jul 3, 2022
Revenues—————
YoY growth—————
Alliance revenues
Total revenues
Costs and expenses:
Cost of sales
Selling, informational and administrative expenses
Research and development expenses
Acquired in-process research and development expenses
Amortization of intangible assets
Restructuring charges and certain acquisition-related costs
Other (income)/deductions––net
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)
Provision/(benefit) for taxes on income/(loss)
Income/(loss) from continuing operations
Discontinued operations––net of tax
Net income/(loss) before allocation to noncontrolling interests
% of revenue—————
Less: Net income attributable to noncontrolling interests
Net income/(loss) attributable to Pfizer Inc. common shareholders
% of revenue—————
Income /loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share)
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share)